Substantial early venous thromboembolism risk with amivantamab plus lazertinib and potential mitigation strategies

Blood Vessels, Thrombosis & Hemostasis · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles